MedTrace Logo

Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones

NCT05789732 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2023-03-31

No results posted yet for this study

Summary

This study will compare the efficacy of silodosin, tadalafil versus silodosin plus tadalafil as Medical Expulsive Therapy (MET) for lower ureteric stones.

Conditions

  • Lower Ureteric Stones
  • Medical Expulsive Therapy
  • Tadalafil
  • Silodosin

Interventions

DRUG

Placebo

Patients will receive placebo treatment once daily.

DRUG

Silodosin

Patients will receive Silodosin 8 mg once daily.

DRUG

Tadalafil

Patients will receive Tadalafil 5 mg once daily.

DRUG

Silodosin and Tadalafil

Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-30
Primary Completion
2022-08-30
Completion
2022-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05789732 on ClinicalTrials.gov